Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
New Insights of Malignant Pleural Mesothelioma
share announcement

New Insights of Malignant Pleural Mesothelioma

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 9949

Special Issue Editors

Prof. Dr. Gregor J. Kocher

E-Mail Website
Guest Editor
Department for BioMedical Research (DBMR), Inselspital, Bern University Hospital, University of Bern, Murtenstrasse 28, CH3008 Bern, Switzerland
Interests: general thoracic surgery; minimally invasive thoracic surgery; chest wall deformities; minimally invasive pediatric surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Georgia Karpathiou

E-Mail Website
Guest Editor
Pathology, North Hospital, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France
Interests: pathology; differential diagnosis; pathogenesis; immunohistochemistry; molecular biology; biomarkers; immune microenvironment; pleural pathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Malignant pleural mesothelioma (MPM), although a relatively rare disease, is one of the most aggressive and most difficult to treat cancers affecting the thoracic cavity. Systemic treatment in the form of chemotherapy as well as local treatment in the form of radiation therapy and/or surgery have all been studied in the past either as a sole treatment option, or in combination with each other, but no treatment regimen has proven to be very effective against MPM.

While the surgical strategy, which focuses on maximal cytoreduction, has evolved from very invasive procedures such as extrapleural pneumonectomy with resection of the pericardium and diaphragm, to less invasive procedures such as pleurectomy/decortication (in selected cases even in the form of minimally invasive video-assisted procedures (VATS)), newer and less toxic systemic agents have also been developed, which are the result of a better understanding of the specific tumor biology. The molecular and morphologic features of this disease are being progressively elucidated and offer a more precise diagnosis.

The aim of this Special Issue is to present the newest developments concerning treatment options for MPM, including basic and translational research, and clinical data of different surgical and combination strategies, but also insights into its pathogenesis, molecular biology, pathology, and diagnosis. In this Special Issue, original research articles and reviews are welcome.

We look forward to receiving your contributions.

Prof. Dr. Gregor J. Kocher
Dr. Georgia Karpathiou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • malignant pleural mesothelioma
  • carcinogenesis
  • chemotherapy
  • chemoresistance
  • immunotherapy
  • checkpoint inhibitors
  • surgery
  • combination therapy
  • pathogenesis
  • diagnosis
  • molecular biology
  • pathology
  • effusion
  • thoracoscopy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1303 KiB  
Article
Incidence and Risk Factors of Chest Wall Metastasis at Biopsy Sites in Patients with Malignant Pleural Mesothelioma
by Masaki Hashimoto, Michiko Yuki, Kazuhiro Kitajima, Akihiro Fukuda, Toru Nakamichi, Akifumi Nakamura, Ayumi Kuroda, Seiji Matsumoto, Nobuyuki Kondo, Ayuko Sato, Koichiro Yamakado, Tohru Tsujimura and Seiki Hasegawa
Cancers 2022, 14(18), 4356; https://doi.org/10.3390/cancers14184356 - 7 Sep 2022
Viewed by 1946
Abstract
To investigate the incidence and risk factors of chest wall metastasis (CWM) at biopsy sites in patients with malignant pleural mesothelioma (MPM). This retrospective cohort study was conducted in 262 consecutive MPM patients who underwent multimodal treatment in which including neoadjuvant chemotherapy (NAC) [...] Read more.
To investigate the incidence and risk factors of chest wall metastasis (CWM) at biopsy sites in patients with malignant pleural mesothelioma (MPM). This retrospective cohort study was conducted in 262 consecutive MPM patients who underwent multimodal treatment in which including neoadjuvant chemotherapy (NAC) and curative-intent surgery, from August 2009 to March 2021. CWM was evaluated radiologically (r-CWM) and pathologically (p-CWM). We also investigated the risk factors of p-CWM and the consistency between r-CWM and p-CWM. Of 262 patients, 25 patients were excluded from analysis due to missing data or impossibility of evaluation. Of the eligible 237 patients, pleural biopsy was performed via video-assisted thoracoscopic surgery in 197 (83.1%) and medical thoracoscopy in 40 (16.9%). Pleurodesis was performed after pleural biopsy in 74 patients (31.2%). All patients received NAC followed by curative-intent surgery. Radiological examination showed r-CWM in 43 patients (18.1%), while pathological examination showed p-CWM in 135 patients (57.0%). The incidence of p-CWM was significantly higher in the patients who received pleurodesis after pleural biopsy (77.0% vs. 47.9%, <0.001). Multivariate logistic regression analysis for p-CWM revealed that pleurodesis is an independent risk factor of p-CWM (adjusted hazard ratio, 3.46; 95% confidence interval, 1.84–6.52, <0.001). CWM at the biopsy site was pathologically proven in more than half of the patients (57.0%) who received NAC followed by curative-intent surgery, which was higher than the numbers diagnosed by radiological examinations (p-CWM: 57.0% vs. r-CWM: 18.1%). Pleurodesis after pleural biopsy is an independent risk factor of p-CWM. Full article
(This article belongs to the Special Issue New Insights of Malignant Pleural Mesothelioma)
►▼ Show Figures

Figure 1

11 pages, 1224 KiB  
Article
A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study
by Giovanni Vicidomini, Carminia Maria Della Corte, Antonio Noro, Raimondo Di Liello, Salvatore Cappabianca, Alfonso Fiorelli, Valerio Nardone, Gaetana Messina, Giuseppe Viscardi, Angelo Sangiovanni, Riccardo Monti, Marina Accardo, Floriana Morgillo, Fortunato Ciardiello, Renato Franco and Mario Santini
Cancers 2022, 14(1), 142; https://doi.org/10.3390/cancers14010142 - 29 Dec 2021
Cited by 3 | Viewed by 4586
Abstract
Background: Multimodality treatment is considered the best treatment strategy for malignant pleural mesothelioma (MPM). However, the ideal combination of them is still a matter of controversy. Here, we report a case series of MPM treated with a trimodality approach: induction chemotherapy (CT), pleurectomy/decortication [...] Read more.
Background: Multimodality treatment is considered the best treatment strategy for malignant pleural mesothelioma (MPM). However, the ideal combination of them is still a matter of controversy. Here, we report a case series of MPM treated with a trimodality approach: induction chemotherapy (CT), pleurectomy/decortication (P/D), postoperative radiotherapy (RT) and post-operative CT. Methods: A retrospective case series of 17 MPM patients treated between 2013 and 2020 is presented. Patients had epithelial or mixed MPM diagnosed by video-assisted thoracoscopy and pathologic IMIG stage I or II disease. Treatment details and radiological data were collected. Induction therapy consisted of combination of cisplatin and pemetrexed, every 21 days for two cycles. P/D was performed 4–6 weeks after induction CT, post-operative RT 3–6 weeks after surgery, while post-operative CT was given 4–6 weeks after RT, with the same schedule of induction. Results: All patients showed objective response or stability of disease at the restaging following induction CT and underwent surgery by posterolateral thoracotomy. There were two cases of cardiac arrest as major intraoperative complication, both resolved by manual cardiac massage. Minor complications included one hemidiaphragm elevation, 1 anemia requiring blood transfusion, one wound infection, and two persistent air leaks. Median overall survival was 32.1 months, median progression free survival was 23.7 months. Conclusions: These results suggest the feasibility of these trimodality treatment scheme for early stage MPM patients. Larger series and long-term prospective studies are needed to confirm the validity of this strategy. Full article
(This article belongs to the Special Issue New Insights of Malignant Pleural Mesothelioma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 601 KiB  
Review
Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?
by Yanyun Gao, Marianna Kruithof-de Julio, Ren-Wang Peng and Patrick Dorn
Cancers 2022, 14(15), 3758; https://doi.org/10.3390/cancers14153758 - 2 Aug 2022
Cited by 3 | Viewed by 2786
Abstract
MPM is an aggressive tumor originating from pleural mesothelial cells. A characteristic feature of the disease is the dominant prevalence of therapeutically intractable inactivating alterations in TSGs, making MPM one of the most difficult cancers to treat and the epitome of a cancer [...] Read more.
MPM is an aggressive tumor originating from pleural mesothelial cells. A characteristic feature of the disease is the dominant prevalence of therapeutically intractable inactivating alterations in TSGs, making MPM one of the most difficult cancers to treat and the epitome of a cancer characterized by a significant lack of therapy options and an extremely poor prognosis (5-year survival rate of only 5% to 10%). Extensive interpatient heterogeneity poses another major challenge for targeted therapy of MPM, warranting stratified therapy for specific subgroups of MPM patients. Accurate preclinical models are critical for the discovery of new therapies and the development of personalized medicine. Organoids, an in vitro ‘organ-like’ 3D structure derived from patient tumor tissue that faithfully mimics the biology and complex architecture of cancer and largely overcomes the limitations of other existing models, are the next-generation tumor model. Although organoids have been successfully produced and used in many cancers, the development of MPM organoids is still in its infancy. Here, we provide an overview of recent advances in cancer organoids, focusing on the progress and challenges in MPM organoid development. We also elaborate the potential of MPM organoids for understanding MPM pathobiology, discovering new therapeutic targets, and developing personalized treatments for MPM patients. Full article
(This article belongs to the Special Issue New Insights of Malignant Pleural Mesothelioma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop